Esketamine: Postmarketing Safety Concerns

<p>How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115"> <strong>Learn more about Premium Memberships here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-27-2591?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115"> <strong>Earn 0.5 CMEs: Quick Take Vol. 27</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/postmarketing-safety-concerns-with-esketamine-a-disproportionality-analysis-of-spontaneous-reports-submitted-to-the-fda-adverse-event-reporting-system-2591-5046?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115"> <strong>Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System</strong></a></li> </ul> <p> </p>